Silo Pharma Files Routine 8-K for 'Other Event' on Feb 1, 2024
Ticker: SILO · Form: 8-K · Filed: Feb 1, 2024 · CIK: 1514183
| Field | Detail |
|---|---|
| Company | Silo Pharma, Inc. (SILO) |
| Form Type | 8-K |
| Filed Date | Feb 1, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: compliance, other-events, administrative
TL;DR
**Silo Pharma filed a routine 8-K, no major news.**
AI Summary
Silo Pharma, Inc. filed an 8-K on February 1, 2024, to report an "Other Event" and provide updated financial statements and exhibits. This filing primarily serves to update the public record with basic company information, including its business address at 677 N. Washington Boulevard, Sarasota, FL 34236, and its telephone number (718) 400-9031. For investors, this filing is routine and indicates ongoing compliance with SEC regulations, but it does not disclose any new material financial or operational developments that would directly impact the stock's value.
Why It Matters
This filing is a standard compliance update, providing no new material information that would significantly affect an investor's decision. It confirms the company's continued adherence to SEC reporting requirements.
Risk Assessment
Risk Level: low — This 8-K is a standard administrative filing and does not introduce any new financial or operational risks.
Analyst Insight
A smart investor would note this as a routine compliance filing and look for other, more substantive filings (like 10-K, 10-Q, or other 8-Ks detailing material events) for actionable insights into Silo Pharma, Inc.'s financial health or strategic direction.
Key Players & Entities
- Silo Pharma, Inc. (company) — the registrant filing the 8-K
- February 1, 2024 (date) — date of earliest event reported and filing date
- 677 N. Washington Boulevard Sarasota, FL 34236 (address) — principal executive offices of Silo Pharma, Inc.
- (718) 400-9031 (phone_number) — registrant's telephone number
- Nevada (state) — state of incorporation for Silo Pharma, Inc.
- 001-41512 (string) — Commission File Number
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 1, 2024, which is also the date of the report.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant as specified in its charter is Silo Pharma, Inc.
Where are Silo Pharma, Inc.'s principal executive offices located?
Silo Pharma, Inc.'s principal executive offices are located at 677 N. Washington Boulevard, Sarasota, FL 34236.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (718) 400-9031.
What items of information were included in this 8-K filing?
This 8-K filing included 'Other Events' and 'Financial Statements and Exhibits' as per the ITEM INFORMATION section.
Filing Stats: 432 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2024-02-01 13:15:35
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SILO The Nasdaq Stock Mar
Filing Documents
- ea192611-8k_silopharma.htm (8-K) — 26KB
- ea192611ex99-1_silopharm.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 10KB
- 0001213900-24-008888.txt ( ) — 222KB
- silo-20240201.xsd (EX-101.SCH) — 3KB
- silo-20240201_lab.xml (EX-101.LAB) — 33KB
- silo-20240201_pre.xml (EX-101.PRE) — 22KB
- ea192611-8k_silopharma_htm.xml (XML) — 3KB
01 – Other Events
Item 8.01 – Other Events On February 1, 2024, Silo Pharma Inc. (the "Company") issued a press release announcing its pipeline prioritization for 2024 targeting mental health, chronic pain and neurology. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated February 1, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -1-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILO PHARMA, INC. Date: February 1, 2024 By: /s/ Eric Weisblum Eric Weisblum Chief Executive Officer -2-